Nevro Receives Approvable Letter from U.S. Food and Drug Administration for Senza Spinal Cord Stimulation System Nevro to Host Investor Conference Call Friday, January 23 at 8:30 a.m. ET Menlo Park, Calif.

Nevro Receives Approvable Letter from U.S. Food and Drug Administration for Senza Spinal Cord Stimulation System

Nevro to Host Investor Conference Call Friday,

January 23 at 8:30 a.m. ET

Menlo Park, Calif., January 22, 2015 Nevro Corp. (NYSE: NVRO), a medical device company that has developed

and commercialized an innovative, evidence-based neuromodulation platform for the treatment of chronic pain, today announced that it has received a letter from the U.S. Food and Drug Administration (FDA) informing the company of the approvability of

its Premarket Approval Application (PMA) for the Senza spinal cord stimulation (SCS) system. According to the approvable letter, approval of the PMA is subject to satisfaction of regulatory inspections and audits of manufacturing facilities, methods

and controls for Senza to ensure compliance with the FDA s Quality System Regulation, as well as finalization of the product s labeling with the FDA.

We are pleased that the FDA has determined our Senza SCS system to be approvable based on the strength of the data provided in the PMA. We are working

to satisfy the conditions of approval and anticipate initial commercial availability in the U.S. by mid-2015 , said Michael DeMane, Chairman and Chief Executive Officer of Nevro. I would like to thank everyone involved in our SENZA-RCT

study, especially the investigators, study coordinators, Nevro employees, and most importantly the patients who consented to participate in the first ever comparative, prospective randomized pivotal trial in the history of spinal cord

Dr. Leonardo Kapural, the lead investigator of the SENZA-RCT study, presented the study results at the Groundbreaking Clinical

Trial Results plenary session of the 2014 North American Neuromodulation Society Meeting in December. The Senza system is commercially available in Europe and Australia where over 2,500 patients have been treated to date.

Investor Conference Call

Nevro will host an investor

conference call beginning at 8:30 a.m. Eastern Time on Friday, January 23, 2015. The conference call can be accessed by dialing (877) 201-0168 domestically and (647) 788-4901 internationally (Conference ID: 72127626), or from the

webcast on the Investors section of the company s website at: www.nevro.com. The webcast will be available on the company s website for two weeks following the completion of the call.

About the Senza System and HF10 Therapy

is the only SCS system that delivers Nevro s proprietary HF10 therapy, an SCS therapy that provides electrical pulses to the spinal cord to alleviate pain. The electrical pulses are delivered by small electrodes on leads that are placed near

the spinal cord and are connected to a compact, battery-powered generator implanted under the skin. As demonstrated in the SENZA-RCT study, HF10 therapy provides pain relief without paresthesia (a constant tingling sensation that is the basis of

traditional SCS therapy).

Headquartered in Menlo Park, California, Nevro is a medical device company focused on providing innovative products that improve the quality of life of

patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the

treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro s proprietary HF10 therapy. In the United States, the Senza system is limited by federal law to investigational use only. Senza, HF10, Nevro and the

Nevro logo are trademarks of Nevro.

Forward-Looking Statements

This press release contains forward-looking statements with respect to our business, strategic initiatives and growth, including statements related to

our expectations about the potential for FDA approval of our PMA for Senza and the timing of commercial availability in the United States. These forward-looking statements are based upon information that is currently available to us or our current

expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including our ability to obtain regulatory approval from the FDA of Senza in the United States, and successfully commercialize Senza;

our ability to manufacture our products to meet demand; the level and availability of third party payor reimbursement for our products; our ability to effectively manage our anticipated growth; our ability to protect our intellectual property rights

and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; additional capital and credit availability; and our ability to attract and retain

qualified personnel. These factors, together with those that are described in greater detail in our reports that we file with the SEC, including our Quarterly Report on Form 10-Q for the third quarter ended September 30, 2014, may cause

our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or

revise any such forward-looking statements.

Investor Relations Contact: